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Abstract
Glioblastoma (GBM) is the most com-
mon and aggressive tumor of the central
nervous system. Unfortunately, patients
affected by this disease have a very poor
prognosis, due to high level of invasiveness
and resistance to standard therapies.
Although the molecular profile of GBM has
been extensively investigated, the events
responsible for its pathogenesis and pro-
gression remain largely unknown. Histone
Deacetylases (HDAC) dependent epigenet-
ic modifications and transforming growth
factor (TGF)-β/Smad pathway seem to play
an important role in GBM tumorigenesis,
resistance to common therapies and poor
clinical outcome. The aim of this study was
to evaluate the involvement and the possi-
ble interaction between these two molecular
cascades in the pathogenesis and prognosis
of GBM. Immunohistochemistry (IHC) was
performed on microdissected GBM sam-
ples, collected from 14 patients (6 men and
8 women) ranging in age from 43 to 74
years. The patients were previously divided,
on the basis of their overall survival (OS),
into two groups: short and long OS. Patients
with poor prognosis showed hyperexpres-
sion of HDAC4 and HDAC6, an activation
of the TGF-β/Smad pathway, with high lev-
els of IL-13, SMAD2, PDGF and MMP3
expression, compared to the long survivors.
The short OS group exhibits a decrease in
SMAD7 expression and also low levels of
p21 immunostaining, which represents a
common target of the two pathways. The
IHC data was confirmed by quantitative
analysis and Immunoblotting. Our prelimi-
nary results suggest that both HDAC4 and
HDAC6 together with the TGF-β/Smad
pathway may be involved in progression of
GBM and this cross talking could be a use-
ful prognostic marker in this deadly disease.
Introduction
Gliomas are the most common group of
primary brain tumors. Glioblastoma (GBM)
defines grade IV of astrocytic tumors show-
ing anaplasia and mitotic activity (anaplas-
tic astrocytoma) and the appearance of
microvascular proliferation and/or
necrosis.1
GBM heterogeneity and genomic insta-
bility confers high capacity of invasion and
refractoriness to several therapies and sur-
vival rates are poor with approximately
only 34% of patients surviving at one year,
12% at two years, and less than 5% at five
years following initial diagnosis. The medi-
an survival rarely exceeds 12 months from
the diagnosis.2
Several genetic alterations have been
supposed to be involved in the etiology of
different grades of astrocytoma, including
epigenetic alterations that result in changes
in gene expression without altering the
DNA sequence per se. Some of the most
thoroughly studied mechanisms in the epi-
genetic regulation of expression are post-
translational histone modification and DNA
methylation (DNA-met) which are poten-
tially reversible.3
Post-translational histone modification
depends on the actions of two main
enzymes, histone acetylases (HAT) and his-
tone deacetylases (HDAC), on the lysines
of histone tails. It is well understood that in
normal cells histone proteins play a central
role in controlling gene expression by mod-
ulating chromatin structure and function
during cell growth and differentiation.
Histone modifications are involved in
tumorigenesis, tumor growth and resistance
to chemotherapy and radiotherapy treat-
ment and for these reasons they are a very
attractive model to treat cancer.4,5 HDACs
are classified into four major classes with
different structure, biological function and
cellular localization and their involvement
in oncogenesis.
Human class I HDACs includes
HDAC1-2-3 and 8 which are proteins simi-
lar to the yeast Rpd3, ubiquitously
expressed in many organs and generally
localized to the nucleus.
Class II HDACs can be subdivided into
two subclasses: IIa, that includes
HDAC4,5,7,9a,9b, and IIb composed of
HDAC6 and 10. Both classes are homolo-
gous to yeast Hda1 and their enzymes can
be located in the nucleus and cytoplasm
suggesting a versatile extranuclear func-
tions.6,7 HDAC class II proteins are abun-
dant in many tissues characterized by low
levels of mitotic activity such as skeletal
muscle, heart and brain.4,7-9 The third class
of HDACs is represented by Sirtuins
(SIRT1-7) which are homologous to the
yeast Sir2 family of proteins and required
NAD+ as enzymatic mechanism for
deacetylase activity, in contrast to the mech-
anism used by class I and II HDACs.
Sirtuins are mainly localized in the nucleus
and mitochondrion.10,11 HDAC class IV
only contains HDAC11, a nuclear HDAC
and it is an additional enzyme phylogeneti-
cally different from both class I and II.12 The
expression of HDAC is frequently altered in
several malignancies and several evidences
indicate that various agents are able to
inhibit HDAC activities inducing growth
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arrest, intrinsic and extrinsic apoptotic
mechanisms, inhibition of angiogenesis in
cancer cells and improvement in NK cell-
mediator tumor immunity.4,13-15 HDAC
inhibitors (HDACIs) as a class of agents
that target the aberrant epigenetic character-
istics of different cancer cells without acting
on DNA sequence, have emerged as a
promising new class of multifunctional
anticancer drugs.16,17
Among the signal transduction path-
ways that play a critical role in GBM, the
transforming growth factor-β (TGFβ) path-
way is involved in the initiation and mainte-
nance of malignant cells. Elevated levels of
this inflammatory cytokine have been found
in the blood of patients with GBM and a
crucial correlation seems to be present
between elevated TGFβ levels, high tumor
grade and poor patients prognosis.18 In nor-
mal conditions, TGFβ is considered a tumor
suppressor as it is an inhibitor of prolifera-
tion in immune cells, epithelial cells and
astrocytes whereas in certain malignant
tumors, including GBM, TGFβ can switch
from tumor suppressor to oncogenic activi-
ty, promoting proliferation, neoangiogene-
sis, immune suppression and metastasis and
extracellular matrix deposition (ECM).19-22
TGFβ signal transduction pathway is
mediated mainly by Smad proteins. Upon
ligand binding and activation of TGFβ
receptors (I, II and III) phosphorylated
SMAD2 and SMAD3 bind with the com-
mon mediator SMAD4. The SMAD2/3-
SMAD4 complex translocates into the
nucleus where it regulates specific TGFβ
target genes.  
In glial cells, TGFβ changes its role
from being a growth inhibitor of normal
glial cells to promoting the proliferation of
neoplastic cells and tumor progression
through the induction of PDGFβ with an
unmethylated PDGFβ gene.23 It has been
demonstrated that in gliomas with low lev-
els of proliferation, the induction of PDGF
by TGFβ/Smad pathway is impaired due to
methylation of the PDGF promoter and
therefore TGFβ/Smad pathway is poorly
efficient. On the contrary, in aggressive
gliomas the PDGFβ gene is not methylated
and TGFβ pathway is hyperactive.23
In order to better understand the molec-
ular mechanisms that govern oncogenesis in
GBM, the aim of this study was to evaluate
the correlation between different HDAC
classes expression and TGFβ/Smad path-
way activity in patients affected by highly
aggressive gliomas with different term sur-
vival.
Materials and Methods
Patients and samples
Fourteen patients with tissue confirmed
diagnosis of GBM (WHO grade IV) were
selected from the Pathology Division
archives of San Salvatore Hospital. Patients
were eligible for the study if a diagnosis of
GBM was established histologically by an
experienced neuropathologist in accordance
with the WHO classification.1 This study
protocol was approved by Institutional
Ethic Committee, University of L’Aquila
(n. 30622).
The patients (8 females, 6 males) were
43 to 73 years old at the time of diagnosis
(mean age 59.8 years; 95% CI 56.22 to
66.82). In all cases, the tumor samples were
obtained before treatment with radiation
and TMZ. After surgery, the patients
received radiotherapy to limited fields (2
Gy per fraction, once a day, 5 days a week,
60 Gy total dose) and concomitant TMZ (75
mg per square meter of body surface area,
per day) for 7 days a week from the first to
the last day of radiotherapy followed by six
cycles of adjuvant TMZ (150-200 mg per
square meter of body surface area on days 1
to 5) given at 4 week intervals. Survival was
calculated from the date of surgery when a
diagnosis of GBM had been established and
on the basis of overall survival5,24 the
patients were divided into 2 groups: short
survival (SS) and long survival (LS).24
Histology and immunohistochemistry 
Samples collected during surgery were
immediately immersed in 4% buffered for-
malin in phosphate buffer saline (PBS pH
7.4) for 12 h at room temperature, then
dehydrated in graded ethanol and embedded
in low-temperature-fusion paraffin for his-
tological and immunohistochemistry stud-
ies. Serial 3 µm-thick sections were stained
with Hematoxylin and Eosin (H&E) in
order to check the extension of the neoplas-
tic area as well GBM histological features
(necrosis, microvascular proliferation and
pseudopalisade arrangement). For immuno-
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Figure 1. Typical histological features of GBM. H&E staining; original magnification: A)
10X; B) 20X; C) 40X; D) 40X. Microphotograph show ‘pseudopalisading’ cells (A, aster-
isks) and colliquative necrosis (B, asterisks), nuclei with phenomena of pyknosis (C,
black head arrows), karyorrhexis (C, arrow) karyolysis (C, white head arrow), and
glomeruloid vascular structures with hyperplastic endothelial cells (D, arrows). 
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histochemical (IHC) analyses 3 µm-thick-
sections were immersed for 40 min in
methanol and 3% hydrogen peroxide solu-
tion and then rinsed in PBS. Thereafter, sec-
tions were incubated overnight at 4°C with
specific antibodies against HDAC1 (sc-
7872), HDAC2 (sc-7899), HDAC3 (sc-
81600), HDAC6 (sc-28386), HDAC8 (sc-
365620) (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) used at a dilution of
1:50, IL-13 (sc-1292), SMAD 2 (sc-6202),
SMAD7 (sc-9183), PDGF (sc-128), MMP3
(sc-6839) and p21 (sc-397) (Santa Cruz
Biotechnology Inc.) used at a dilution of
1:100 and HDAC4 (Ab 632-A00429)
(GenScript, Piscataway, NJ, USA) used at
dilution 1:50. 
The samples were washed in PBS three
times, for 2 min and then incubated with
HRP conjugated antirabbit IgG secondary
antibody (SV0002-1, Boster Biological
Technology, Ltd., Pleasanton, CA, USA)
for HDAC1,2,4 and PDGF (SV0001-1,
Boster Biological Technology, Ltd.), for
HDAC3,6,8 with HRP conjugated anti-
mouse IgG secondary antibody (SV0001-1,
Boster Biological Technology, Ltd) and
with HRP conjugated antigoat IgG second-
ary antibody (SV0001-3, Boster Biological
Technology, Ltd).
After three washes in PBS for 10 min,
the sections were subject to incubation with
3,3'-Diaminobenzidine-tetrahydrochloride
(DAB, Sigma Aldrich, Milan, Italy) for 1-3
min. The specificity of immune reaction
was revealed by keeping off the primary
antibodies. Finally, the samples were
stained with Hematoxylin of Mayer and
observed under the Olympus BX51 Light
Microscope (Olympus, Optical Co. Ltd.,
Tokyo, Japan). Observations were
processed with an image analysis system
(IAS, Delta system, Rome, Italy) and were
independently performed by two patholo-
gists (RS, AV) in a blinded fashion.
Quantitative digital image analysis
of immunohistochemical staining
The sections were observed at 20X and
quantitative comparison of immunohisto-
chemical staining was measured by the
ImageJ digital image analysis public
domain software.25 The IHC profiler soft-
ware plugin was required.26 The
immunopositivity was expressed as a per-
centage of the total software-classified
areas and the data obtained were plotted as
histograms. 
Immunofluorescence
Serial 3-µm sections from SS and LS
patients were immersed in 5% PBS Bovine
Serum Albumine (BSA) for 1 h at room
                             Original Paper
Figure 2. Class I HDAC expression in GBM. Immunohistochemistry; original magnifi-
cation: 20X. Class I HDAC genes (HDAC1,2,3,8) shows lower levels of expression with-
out significantly differences among LS and SS of patients. 
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temperature in order to prevent non-specific
bindings. Samples were then incubated
overnight at 4°C with HDAC6 antimouse
and SMAD7 antigoat antibodies used at
1:100 dilution. After three washes in PBS
for 10 min, the sections were incubated for
30 min at room temperature with secondary
fluorescent antibodies donkey antigoat IgG-
FITC and goat antimouse IgG-TR (Santa
Cruz Biotechnology Inc.) used at dilution
1:200 and 1:100 respectively. Nuclei were
treated with 4’,6-diamidino-2-phenylindole
(DAPI) at dilution 1:10, for 5 min at room
temperature. Negative controls were
obtained by keeping off the primary anti-
bodies. Finally, the samples were observed
under the Zeiss Axio Imager 2 with DFC
250 video camera (Carl Zeiss Microscopy,
LLC, Thornwood, NY, USA). Micro-
photographswere processed with Image J
software and analyzed by two pathologists
(AV, RS) in a blinded fashion.
Cell cultures, shRNA transfection,
radiation exposure, tumor sphere
and colony formation assays
The human GBM cell lines, U118MG,
U138MG and U251MG, cell lines were
obtained from the American Type Culture
Collection (Rockville, MD, USA). NHA
(normal human astrocytes) cell line was
obtained from the LONZA (Rockville, MD,
USA). Cells were maintained according to
the manufacturer’s instructions in
Dulbecco’s modified Eagle’s medium with 4
mM L-glutamine, 1.5 g/L sodium bicarbon-
ate, 4.5 g/L glucose, 10% fetal bovine serum.
Periodically, DNA profiling using the
GenePrint 10 System (Promega Corporation,
Madison, WI, USA) was carried out to
authenticate cell cultures, by comparing the
DNA profile of our cell cultures with those
found in GenBank. A pool of 3 target-specif-
ic 19-25 small interfering RNAs (siRNAs)
were used to knock-down HDAC6 (sc-
35544, Santa Cruz Biotechnology, Ltd.) gene
expression. Transfections were performed
following Santa Cruz Biotechnology’s
instructions, by using siRNA Transfection
Reagent (sc-29528), siRNA Transfection
Medium (sc-36868) and siRNA Dilution
Buffer (sc-29527).
Preparation of cell lysates and
Western blot analysis 
Tumor cells were plated (5×105
cells/dish) in 10-cm dishes, for 72 h. After
this time, adherent cells were harvested and
lysed in RIPA buffer; protein preparations
(30-40 μg) were resuspended in reducing
Sample buffer (Bio-Rad Laboratories,
Segrate, Mi, Italy) and heated at 95°C for 5
min. Following electrophoretic separation
by SDS-PAGE, proteins were transferred
onto nitrocellulose membrane. After block-
ing, membranes were incubated with the
primary antibodies against HDAC-6,
SMAD7, α-actin and α-tubulin. Detection
was done using horseradish peroxidase-
conjugated secondary antibodies, and
enhanced chemiluminescence ECL-Prime
reagents. Total extracts were normalized by
using an anti α-tubulin antibody.
In vitro radiation treatment and sur-
viving fraction analysis
Radiation was delivered at room tem-
perature using an x-6 MV photon linear
accelerator, as previously described.27,28 In
brief, the total single dose of 4 Gy was
delivered with a dose rate of 2 Gy/min using
a source-to-surface distance (SSD) of 100
cm. A plate of Perspex thick 1.2 cm was
positioned below the cell culture flasks in
order to compensate for the build-up effect.
Tumor cells were then irradiated placing the
gantry angle at 180°. Non-irradiated con-
trols were handled identically to the irradi-
ated cells with the exception of the radiation
exposure.
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Figure 3. Class II HDAC expression in GBM. Immunohistochemistry; original magnification: 40X. HDAC4,6 are increased in patients
with short overall survival. Data are confirmed by quantitative analyses. 
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Statistical analysis
Statistical analysis was performed using
Students’ t-test for comparison of two
groups and one-way ANOVA test for more
than two groups. Continuous variables were
expressed as means ± SD. A P-value <0.05
was considered statistically significant. 
Results
Microscopy, immunohistochemistry
and immunofluorescence
Histopathologic examination showed
necrotic and hemorrhagic foci surrounded by
‘pseudopalisading’ cells in a configuration that
is relatively typical to glioblastomas. Different
morphological features of cell death as apopto-
sis and colliquative necrosis with cellular
nuclei that exhibit phenomena pyknosis, kary-
olysis and karyorrhexis. Glomeruloid vascular
structures with hyperplastic endothelial cells
were also present (Figure 1). Class I HDAC
genes (HDAC1,2,3,8) showed lower levels of
expression without significantly differences
among the two groups of patients (Figure 2).
The immunopositivity of HDAC4,6 was
increased in patients with short survival com-
pared to long. These data were confirmed by
quantitative analyses (Figure 3). Quantitative
evaluation of immunohistochemical staining
showed a significantly increased expression of
IL13, SMAD2 and PDGF in SS patients com-
pared to LS patients in which the immunopos-
itivity was mild and/or very low (Figure 4). On
the other hand, a significant reduction of
SMAD7 in SS patients was found (Figure 4).
Finally, the MMP3 immunopositivity was sig-
nificantly higher in SS patients respect to LS
(Figure 4). These results were in accordance
with those obtained by quantitative analyses
with a statistically significant difference
among two groups of patients (P≤0.05) (Figure
4). In SS patients p21 immunostaining showed
a low positivity compared to LS and also these
results were in accordance with those obtained
by quantitative analyses with a statistically sig-
nificant difference among two groups of
patients (P≤0.01) (Figure 5). Double immuno-
fluorescence analysis showed a localization of
both SMAD7 and HDAC6 in neoplastic cells.
In particular, in SS patients, HDAC6 signal
was prevalent respect to SMAD7 whereas in
LS we observed the contrary (Figure 6).
High HDAC6 and low SMAD7
expression predict GBM radiation
sensitivity 
Radiosensitivity was assessed by clono-
genic assays, in a panel of glioblastoma
cells (Figure 7A). Survival (S) data after a
radiation dose (D) was fitted by a weighted,
stratified, linear regression according to the
linear-quadratic formula as described in
materials and methods. U251MG, U118MG
and U138MG respectively showed a high,
intermediate and low radiosensitivity with a
surviving fraction that decreased in a dose
dependent manner (Figure 7A). HDAC6,
SMAD7 expression levels and cell lines
radioresensitivity were cross-matched.
Decreasing levels of HDAC6 (Figure 7
B,C) or increasing of SMAD7 (Figure 7
B,C) were directly related to GBM
radiosensitivity (Figure 7D). The relation-
ship between HDAC6, SMAD7 expression
and GBM radiosensitivity was confirmed
by silencing HDAC6 expression in
U138MG highly radioresistant cell line (Fig
8). Silencing HDAC6 increased SMAD7
protein expression (Figure 8A) inducing a
significant (P<0.05) dose-dependent
radiosensitization of U138MG cells (Figure
8B).   
Discussion
GBM’s genetic profiling has been thor-
oughly studied in order to identify the alter-
ations responsible for its pathogenesis and
progression. Among these alterations it was
possible to observe epimutations that regu-
late gene expression without modifying the
DNA sequence.3 Epimutations affect his-
tones through a variety of post-translational
modifications. Variations in histone acetyla-
tion levels, caused by the opposing enzy-
matic activities of HATs and HDACs,
involve histone tails rich in lysine, arginine
and serine. Lysine deacetylation induced by
HDACs causes an increase in positive
charge density, leading to a stronger interac-
tion with the DNA and, consequently, to a
more compact chromatin structure associat-
ed to a transcriptional inactivity of some
genes, among which many proto-onco-
genes.29,30 It has been demonstrated that
mRNA expression of Class I HDACs does
not reveal significant statistic differences
between GBM, low-grade gliomas and nor-
mal brain tissue, so that these molecules
may not directly influence the prognosis.
On the contrary, class II and IV HDACs’
levels are lower in GBM.5 In our study the
immunohistochemical analysis showed that
HDAC1, 2, 3 and 8 were slightly expressed
in the two groups of patients whereas
immunopositivity for HDAC4,6 was signif-
icantly higher in patients with low overall
survival. These data are strongly related to
radiation therapy bad response and to the
outcome of GBM patients. It is conceivable
that GBM pathogenesis and aggressiveness
are not only determined by epimutations but
also by HDACs action on non-histone sub-
strates.31 Multiple pathways are associated
with gliomas and the TGFβ/Smad can be
considered a very crucial signaling not only
in tissue remodeling and fibrosis in many
organs,21 but also in regulating tumor pro-
gression due to its oncogenic role.32
Different proteins of the TGF-β/Smad path-
way are known to be hyperexpressed in
high-grade gliomas32 resulting in overex-
pression of some target molecules such as
PDGF and MMP3 involved in ECM
rearrangement that leads to GBM invasive-
ness.33,34 In our study, SS group of patients
showed a marked immunopositivity of the
upstream proteins (IL-13, SMAD2) and
final effector proteins (PDGF, MMP3) of
the cascade whereas in the same group
immunohistochemistry analyses showed a
very mild expression of SMAD7. On the
contrary, the molecular pathway in the LS
group was less active at all levels, both
upstream and downstream, showing instead
a higher immunopositivity of SMAD7.
SMAD7 function is influenced by the local-
ization in the various cell compartments and
by the modulation of the protein stability,
depending on the opposing action of HATs
and HDAC different isoforms.33 In addition,
SMAD7 participates in the formation of the
HDAC1/SMAD7/E2F-1 ternary complex
that is involved in regulating gene transcrip-
tion, and thus in controlling cell prolifera-
tion.35 In our study, we noticed that in SS
patients immunofluorescence analysis
showed that SMAD7 signal was very low
respect to HDAC6. Therefore, it seems
plausible that SMAD7 deacetylation in
GBM may depend on the action of HDAC6. 
Although the meaning of our findings is
still partly uncertain, we may hypotize the
possible role of HDAC6 in a protein com-
plex acting as transcriptional modulator
besides the well-known interaction between
deacetylates and SMAD7 lysine.36
Considering the expression of the different
tested proteins, we suggest that the modula-
tion of the acetylation level may influence
TGF-β/Smad signaling activity. These pre-
liminary findings suggest a possible
crosstalking between HDACs and the TGF-
β/Smad pathway and it seems able to influ-
ence the prognosis of GBM, since TGF-β
hyperactivity and HDACs expression pro-
mote proliferation and cell survival, partly
responsible for the neoplasm’s refractori-
ness to standard treatments. TGF-β acts as a
proliferation inhibitor in many cells and its
cytostatic activity is also due to induction of
cyclin-dependent kinase inhibitors like
p21.37 In the light of these considerations
regarding the activity of TGF-β/Smad path-
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Figure 4. TGF-β/Smad pathway and MMP3 expression in GBM. Immunohistochemistry; original magnification: 20X. IL-13, SMAD2,
PDGF and MMP3 immunostaining are significantly increased in SS patients compared to LS patients. SMAD7show a significant reduc-
tion of in SS patients. 
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Figure 5. p21 expression in GBM. Immunohistochemistry; original magnification: 40X. In SS patients p21 immunostaining shows a
low positivity compared to LS. 
Figure 6. Double immunofluorescences analysis for SMAD7 and HDAC6 in LS and SS patients.  Microphotographs show a red signal
for HDAC 6 and a green signal for SMAD7. HDAC6 expression is prevalent respect to SMAD7 in SS patients (white arrow) whereas
in LS patients SMAD7 immunopositivity is higher respect to HDAC6 (white head arrow); original magnification:  40X. 
way, p21 levels in group SS might be
expected to be rather high. On the contrary,
patients with most unfavorable prognosis
showed lower levels in comparison to the
other group. This result may be explained
through the TGF-β paradox theory,19,38
according to which the pathway functional
switch from tumor suppressor to tumour
promoter may at least partially depend on
TGF-β inability to induce p21.23,39
Hypothesizing that all other functions
of the cascade remain unaltered, the TGF-β
paradox theory also explains the simultane-
ous expression of other target molecules
such as MMP3 and PDGF. An alternative
explanation is based on HDAC capacity to
suppress p21 activity, as demonstrated in
manyother tumors,40,41 and in our results we
hypnotize that p21 hypoexpression in SS
group may be linked to p21 repression by
HDAC4 or HDAC6, that are more
expressed in the same group of patients.
Taken together, our data may suggest that
HDAC4, HDAC6 and TGF-β pathway’s
proteins may be considered among GBM
prognostic markers. Limitation to this study
includes the small number of patients and
although our findings seem to indicate an
association between HDAC4,6 and the
TGF-β/Smad pathway further research is
needed to confirm these preliminary data in
order to improve disease control and current
standard therapy.
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Figure 7. High HDAC6 and low SMAD7 expression correlate with GBM radiosensitivity. The glioblastoma cell lines were plated at clonal den-
sity for clonogenic assay and treated with ionizing radiation (0-6Gy). Cells were left for further 14 days when cultures were stained with 10%
crystal violet in methanol and stained colonies were counted. Each point represented the mean surviving fraction calculated from three inde-
pendent experiments done in triplicate for each treatment condition; error bars represent the standard deviation (SD) (A). Western blot analysis
(B) was carried out with an anti-HDAC-6 and anti-SMAD7 antibodies according to manufacturer's instructions. C,D) Densitometric evalu-
ation of HDAC-6 and SMAD7 expression levels. One representative of three different experiments is shown for each of the analyses performed.
Figure 8. Silencing HDAC6 downregulates SMAD7 protein expression levels and radiosensitizes U138MG cells. U138MG cell lines were
transiently transfected with siRNA for HDAC6: 72 h later, cells were assessed for HDAC6 and SMAD7 expression levels by Western blot
(A) and treated or not with increasing doses of ionizing radiation (0-6 Gy) (B). Cells were left for further 14 days when cultures were stained
with 10% crystal violet in methanol and stained colonies were counted. Each point represented the mean surviving fraction calculated from
three independent experiments done in triplicate for each treatment condition; error bars represent the standard deviation (SD).
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